TG4050 TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings Article available for the first time on Nature Communications website – Download the Article
Category: Myvac
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
medRxiv 2026
TG4050 at 2025 SITC: New Ph.I immunological data
link to webcast
VacDesignR®: a Tool for Optimizing Recombinant Poxvirus Vaccine Production
B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster
Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC
C. Le Tourneau, et al. SITC 2025 Abstract available on JITC website – Download the abstract – Download the Poster
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
ESMO AI 2026
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
Title SITC
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025
H1 financial resultats
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
TG4050
Listen to Prof. Ottensmeier explain the TG4050 Phase 1 data
link to webcast